Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85186 trials found · Page 45 of 4260
-
One-Shot gene therapy aims to halt Muscle-Wasting disease
Disease control Recruiting nowThis is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
One-Shot vision treatment could replace frequent eye injections
Disease control Recruiting nowA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
One shot a year to stop HIV? major trial tests new prevention method
Prevention Recruiting nowThe goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophy…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Apr 20, 2026 16:16 UTC
-
New hope for Alzheimer's memory loss in major drug trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
New hope for advanced breast cancer: major trial tests promising drug
Disease control Recruiting nowResearchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Laser zaps brain to stop seizures in new trial
Disease control Recruiting nowHow does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Radical early brain surgery could save lives after massive strokes
Disease control Recruiting nowEarly Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard…
Phase: NA • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New injection challenges standard pill in fight against tough blood cancer
Disease control Recruiting nowThe main objective of this study is to evaluate the differences in objective response rate and overall survival between the Purinostat mesylate for injection and selinexor, as assessed by blinded independent central review (BICR), in patients with relapsed or refractory diffuse l…
Phase: PHASE3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
New drug trial offers hope for advanced breast cancer patients who ran out of options
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New drug trial aims to halt inherited bowel cancer risk
Disease control Recruiting nowThe main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are: * Does tak…
Phase: PHASE3 • Sponsor: Rapamycin Holdings Inc. • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Revolutionary Cancer-Fighting technique tested to halt rogue immune attacks
Disease control Recruiting nowThis is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Breakthrough trial tests Next-Generation drug against aggressive lung cancer
Disease control Recruiting nowMulticenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small …
Phase: PHASE3 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
New bladder cancer treatment aims to outsmart recurrence
Disease control Recruiting nowThis phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemother…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
One-Shot gene therapy creates Cancer-Fighting cells inside Patients' bodies
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
New hope for advanced colon cancer: trial tests targeted drug combo
Disease control Recruiting nowResearchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizum…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
First-Ever gene editing attempt for devastating immune disease
Disease control Recruiting nowBackground: X-linked hyper-IgM (HIGM) syndrome is caused by a mutation in the CD40 ligand (CD40L) gene. People with this disease have white blood cells that do not work properly. These people are at risk of severe infections and autoimmune diseases. Researchers want to know if t…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New Alzheimer's drug combo aims to slow memory decline in major trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
Experimental cell therapy aims to reset immune system in Tough-to-Treat lupus
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Scientists test 'Living Drug' to tame severe lupus
Disease control Recruiting nowA clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evalu…
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New combo therapy aims to stop liver cancer recurrence in High-Risk patients
Disease control Recruiting nowThis study is an open-label, randomized controlled, multicenter, phase III clinical trial
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC